In this study, we compared two human melanoma cell lines that differed in their oncogene profile (BRAFV600E and BRAFwt) causing altered sensitivities to classical chemotherapeutics and PLX4032, an inhibitor of mutated BRAF. The gene discussed is BRAF; the disease is melanoma.